The ~$235M net proceeds provide a multi-year runway for VS-7375 development, including the Phase 3 first-line mPDAC trial expected to open by year-end 2026. The offering was priced at a premium to the prior close, suggesting strong institutional demand. Watch for the Q3 2026 10-Q filing for audited financials and updated cash burn guidance, and monitor VS-7375 enrollment updates and the blister-pack NDA decision in Q1 2027.
Price Chart
Executive Summary
Verastem priced a $250M underwritten public offering of 30,937,500 common shares at $8.00/share (a ~7.4% premium to the $7.45 prior close) plus pre-funded warrants for 312,503 shares. Net proceeds of ~$234.7M will fund VS-7375 clinical development and working capital. The offering follows strong preliminary Q3 2026 revenue of ~$24M (more than double YoY), positive VS-7375 Phase 1/2 data, and FDA acceptance of a blister-pack NDA with priority review. The capital raise is dilutive (~34% share count increase) but extends the cash runway to fund the KRAS G12D pipeline through key catalysts.
Key Facts
- Offering of 30,937,500 common shares at $8.00/share plus 312,503 pre-funded warrants at $7.9999 each, total gross proceeds ~$250M
- Net proceeds to Verastem ~$234.7M after underwriting discounts and estimated expenses of $300K
- Offering price of $8.00 represents a ~7.4% premium to the October 13, 2026 closing price of $7.45
- Pro forma shares outstanding of 121,419,115 (excluding pre-funded warrant exercise), a ~34% increase from 90,481,615 shares outstanding as of June 30, 2026
- Immediate dilution of $5.79 per share to new investors based on as-adjusted net tangible book value of $2.21 per share
- Preliminary Q3 2026 net product revenue estimated at $23.9M-$24.1M, up from $11.2M in Q3 2025
- Cash, cash equivalents and investments as of September 30, 2026 estimated at $172.8M, up from $137.7M a year earlier
- Proceeds intended to fund continued clinical development of VS-7375 (KRAS G12D inhibitor) and for working capital
- FDA accepted blister-pack NDA for priority review on October 7, 2026, with target action date in Q1 2027
- CEO Daniel Paterson retiring effective January 1, 2027; Michael Bailey appointed as successor
- 60-day lock-up agreements for company, executive officers, and directors
- Underwriters include Jefferies, Guggenheim Securities, Cantor Fitzgerald, and B. Riley Securities
Financial Impact
~$250M gross equity raise at a small premium to market, resulting in ~34% share dilution. Net proceeds of ~$234.7M extend cash runway to fund VS-7375 development through key Phase 3 data readouts.
Risk Factors
- Immediate and substantial dilution of ~34% to existing shareholders
- Potential for further dilution from outstanding options, RSUs, and pre-funded warrants
- Preliminary Q3 financials are unaudited and subject to revision
- CEO transition adds execution risk during a critical pipeline period
- Clinical development of VS-7375 may take longer or cost more than planned
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-115879 |
| Document: 0001104659-26-115879-index-headers.html | 0001104659-26-115879 |
| Document: 0001104659-26-115879-index.html | 0001104659-26-115879 |
| Document: 0001104659-26-115879.txt | 0001104659-26-115879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 8-K | $9.23 | awaiting T+60 | — | $10.11 (−9.59%) |
Oct 14, 2026 11d ago | 424B5 | $9.23 | awaiting T+60 | — | $10.11 (−9.59%) |
Oct 14, 2026 11d ago | 424B5 | $9.23 | awaiting T+60 | — | $10.11 (−9.59%) |
Oct 14, 2026 12d ago | 8-K | $7.71 | awaiting T+60 | — | $10.11 (+31.19%) |
Oct 2, 2026 23d ago | Insider Cluster | $8.00 | awaiting T+60 | — | $10.11 (−26.44%) |
Jun 23, 2026 17w ago | 8-K | $3.85 $7.55 | ▲ +96.10% | ▲ +93.27% | $10.11 (+162.73%) |
Jun 17, 2026 18w ago | 8-K | $4.17 $7.32 | ▲ +75.54% | ▲ +72.39% | $10.11 (+142.57%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.10 $8.08 | ▲ +97.07% | ▲ +93.81% | $10.11 (+146.71%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.94 $8.20 | ▲ +108.12% | ▲ +103.73% | $10.11 (+156.73%) |
May 27, 2026 21w ago | 3 | $4.29 $6.89 | ▲ +60.61% | ▲ +58.87% | $10.11 (+135.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers